Evidence map›Paper›PMID 36930680›Full record

ArticlePloS one2023

Staphylococcus aureus binding to Seraph® 100 Microbind® Affinity Filter: Effects of surface protein expression and treatment duration.

Malin-Theres Seffer, Martin Weinert, Gabriella Molinari, Manfred Rohde, Lothar Gröbe, Jan T Kielstein, Susanne Engelmann

Open access · goldFull text read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Novel extracorporeal therapies in children.Pediatric nephrology (Berlin, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Macrophage activation syndrome in Sepsis: from pathogenesis to clinical management.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Review
  6. The Seraph 100Antibodies (Basel, Switzerland) · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Malin-Theres SefferHelmholtz Centre for Infection Research, Microbial Proteomics, Braunschweig, Germany.
Martin WeinertHelmholtz Centre for Infection Research, Microbial Proteomics, Braunschweig, Germany.
Gabriella MolinariHelmholtz Centre for Infection Research, Central Facility of Microscopy, Braunschweig Germany.
Manfred RohdeHelmholtz Centre for Infection Research, Central Facility of Microscopy, Braunschweig Germany.
Lothar GröbeHelmholtz Centre for Infection Research, Experimental Immunology, Braunschweig, Germany.
Jan T KielsteinMedical Clinic V, Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany.
Susanne EngelmannHelmholtz Centre for Infection Research, Microbial Proteomics, Braunschweig, Germany.ORCID 0000-0002-1201-3488
Helmholtz Centre for Infection Research · DEKlinikum Braunschweig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionExtracorporeal blood purification systems represent a promising alternative for treatment of blood stream infections with multiresistant bacteria.

objectivesThe aim of this study was to analyse the binding activity of S. aureus to Seraph affinity filters based on heparin coated beads and to identify effectors influencing this binding activity.

resultsTo test the binding activity, we used gfp-expressing S. aureus Newman strains inoculated either in 0.9% NaCl or in blood plasma and determined the number of unbound bacteria by FACS analyses after passing through Seraph affinity filters. The binding activity of S. aureus was clearly impaired in human plasma: while a percent removal of 42% was observed in 0.9% NaCl (p-value 0.0472) using Seraph mini columns, a percent removal of only 10% was achieved in human plasma (p-value 0.0934). The different composition of surface proteins in S. aureus caused by the loss of SarA, SigB, Lgt, and SaeS had no significant influence on its binding activity. In a clinically relevant approach using the Seraph® 100 Microbind® Affinity Filter and 1000 ml of human blood plasma from four different donors, the duration of treatment was shown to have a critical effect on the rate of bacterial reduction. Within the first four hours, the number of bacteria decreased continuously and the reduction in bacteria reached statistical significance after two hours of treatment (percentage reduction 64%, p-value 0.01165). The final reduction after four hours of treatment was close to 90% and is dependent on donor. The capacity of Seraph® 100 for S. aureus in human plasma was approximately 5 x 108 cells.

conclusionsThe Seraph affinity filter, based on heparin-coated beads, is a highly efficient method for reducing S. aureus in human blood plasma, with efficiency dependent on blood plasma composition and treatment duration.

Indexed as

Staphylococcal InfectionsStaphylococcus aureusBacteriaDuration of TherapyHeparinHumansMembrane ProteinsSaline SolutionHeparinMembrane ProteinsSaline Solution

Identifiers

PMID36930680
PMCPMC10022791
OpenAlexW4327682108

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read52
identifiers read9
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.